April 30, 2020
The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial
59% Complete Response in patients with low-grade upper tract urothelial cancer Kaplan-Meier analysis, based on interim data, estimated 12-month durability…
